*Disclaimer

ONCOSIL MEDICAL LTD (ASX: OSL)

🔗 📄 📈

OSL: Multi-Centre Data on OncoSil in Metastatic Pancreatic Cancer

ONCOSIL MEDICAL LTD

2023-06-30 09:49:00

OSL: Ethics Committee Approves PANCOSIL Clinical Trial

ONCOSIL MEDICAL LTD

2023-06-05 09:31:00

OSL: First patient treatment in Italy

ONCOSIL MEDICAL LTD

2023-05-22 09:11:00

OSL: First patient enrolled in the TRIPP-FFX Clinical Study

ONCOSIL MEDICAL LTD

2023-05-03 08:47:00

OSL: OncoSil to streamline operating structure

ONCOSIL MEDICAL LTD

2023-05-02 08:48:00

OSL: First year anniversary of the OSPREY post-marketing registry

ONCOSIL MEDICAL LTD

2023-05-01 09:25:00

OSL: Oral presentation at The Mayo Clinic IMPACT Course

ONCOSIL MEDICAL LTD

2023-04-24 09:16:00

OSL: Further commercial milestones achieved in Spain

ONCOSIL MEDICAL LTD

2023-04-24 09:15:00

OSL: Additional Binding Commitment Received for Entitlement Offer

ONCOSIL MEDICAL LTD

2023-04-21 10:02:00

OSL: Commitment received for Offer and updated Timetable

ONCOSIL MEDICAL LTD

2023-03-17 11:35:00

OSL: Two key treatment centres treat first patients with OncoSil

ONCOSIL MEDICAL LTD

2023-01-31 08:40:00